Russek-Blum Niva 4

What Happened
Niva Russek-Blum, Chief Technology Officer of NeuroSense Therapeutics Ltd. (NRSN), received a grant of 200,000 restricted ordinary shares on March 26, 2026. The shares were issued at $0.00 per share (no cash paid) — an equity award as part of compensation rather than an open-market purchase or sale. The Form 4 was filed March 30, 2026.

Key Details

• Transaction type: Award/Grant (Form 4 code A).
• Transaction date: 2026-03-26; Filing date: 2026-03-30 (timely — within two business days).
• Price: $0.00 per share; total cash paid: $0.
• Shares granted: 200,000 restricted shares.
• Shares owned after transaction: not specified in the filing.
• Footnote: For Israeli tax benefits under Section 102, the shares must be registered in the name of a trustee.
• Vesting: Restricted shares vest in equal quarterly installments over two years starting March 26, 2026, subject to continued service.

Context
This is a compensation award (restricted stock) rather than a market buy or sale; vested shares typically become tradable only as they vest and may be subject to transfer restrictions and tax treatment. Such grants are common for employee retention and do not by themselves indicate an insider buying or selling shares on the open market.